<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03968848</url>
  </required_header>
  <id_info>
    <org_study_id>ACE-HI-102</org_study_id>
    <nct_id>NCT03968848</nct_id>
  </id_info>
  <brief_title>Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite</brief_title>
  <official_title>A Phase 1, Open-Label, Single-Dose Study to Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite (ACP-5862)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acerta Pharma BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Acerta Pharma BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is investigate the influence of severe hepatic impairment on the pharmacokinetics
      of acalabrutinib and its metabolite.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 12, 2018</start_date>
  <completion_date type="Actual">March 29, 2019</completion_date>
  <primary_completion_date type="Actual">March 13, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of Acalabrutinib (ACP-196) to evaluate Area Under the Concentration-Time Curve (AUC)</measure>
    <time_frame>Study Days 1, 2, 3 and 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent total plasma clearance after oral administration</measure>
    <time_frame>Study Days 1, 2, 3 and 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration</measure>
    <time_frame>Study Days 1, 2, 3 and 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach Cmax</measure>
    <time_frame>Study Days 1, 2, 3 and 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of the last measurable concentration</measure>
    <time_frame>Study Days 1, 2, 3 and 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination rate constant</measure>
    <time_frame>Study Days 1, 2, 3 and 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent first-order terminal elimination half-life</measure>
    <time_frame>Study Days 1, 2, 3 and 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution during the terminal elimination phase after oral administration</measure>
    <time_frame>Study Days 1, 2, 3 and 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fraction of unbound drug in plasma</measure>
    <time_frame>Study Days 1, 2, 3 and 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events</measure>
    <time_frame>Study Days 1, 2, 3, 4 and follow-up occurring 14 days after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Hepatic Impairment</condition>
  <condition>Hepatic Insufficiency</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Subjects with Severe Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with severe hepatic impairment (score of 10 to 15 on the Child-Pugh scale) will be administrated a 50-mg single oral dose of acalabrutinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched-Control Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with normal hepatic function will be administrated a 50-mg single oral dose of acalabrutinib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acalabrutinib</intervention_name>
    <description>A 50-mg single oral dose of acalabrutinib will be administered.</description>
    <arm_group_label>Matched-Control Subjects</arm_group_label>
    <arm_group_label>Subjects with Severe Hepatic Impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Women must be of non childbearing status

          -  Understands the study procedures in the ICF and be willing and able to comply with the
             protocol.

          -  Willingness and ability to swallow study drug capsule.

          -  Adult men or women, 18 to 75 years of age

        Hepatic-Impaired Subjects Only:

          -  Subject has a diagnosis of chronic, stable HI.

          -  Subject's score on the Child-Pugh scale must range from 10 to 15 at screening.

        Exclusion Criteria

          -  History or presence of clinically significant or unstable medical or psychiatric
             condition or disease in the opinion of the PI.

          -  Dosed in another clinical trial within 28 days before dosing of study drug and
             throughout the current study.

          -  History or presence of drug abuse within 2 years before screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>United States, Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States, Florida</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States, Tennessee</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>May 29, 2019</last_update_submitted>
  <last_update_submitted_qc>May 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic</keyword>
  <keyword>Acalabrutinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

